These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 20429725

  • 1. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M, Schønnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P.
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ, Ryu MH, Kang HJ, Lee SS, Chang HM, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
    Dupont J, Jensen HA, Jensen BV, Pfeiffer P.
    Acta Oncol; 2007 Jul; 46(3):330-5. PubMed ID: 17450468
    [Abstract] [Full Text] [Related]

  • 4. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, Tentes A, Deftereos S, Karanikas M, Karayiannakis A, Kakolyris S.
    Oncology; 2011 Jul; 80(5-6):359-65. PubMed ID: 21811088
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D, Miner T, Akerman P, Millis R, Jean M, Kennedy T, Safran H.
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [Abstract] [Full Text] [Related]

  • 6. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.
    Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ.
    Acta Oncol; 2014 Mar; 53(3):392-8. PubMed ID: 24024696
    [Abstract] [Full Text] [Related]

  • 7. A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
    Malik I, Bernal P, Byrd J.
    Cancer Invest; 2010 Oct; 28(8):833-8. PubMed ID: 20839949
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD.
    J Clin Oncol; 2010 May 01; 28(13):2213-9. PubMed ID: 20351330
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
    Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P.
    Ann Oncol; 2015 Jan 01; 26(1):149-156. PubMed ID: 25416687
    [Abstract] [Full Text] [Related]

  • 10. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
    Pluschnig U, Schoppmann SF, Preusser M, Datler P, Asari R, Ba-Ssalamah A, Schwameis K, Birner P, Zacherl J, Hejna M.
    Anticancer Res; 2013 Mar 01; 33(3):1035-9. PubMed ID: 23482778
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):277-84. PubMed ID: 22752217
    [Abstract] [Full Text] [Related]

  • 12. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
    Amarantidis K, Xenidis N, Chelis L, Chiotis A, Tentes A, Chatzaki E, Kortsaris A, Polychronidis A, Karakitsos P, Kakolyris S.
    Acta Oncol; 2010 Aug 01; 49(2):245-51. PubMed ID: 19839918
    [Abstract] [Full Text] [Related]

  • 13. New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
    Schønnemann KR, Yilmaz M, Andersen M, Pfeiffer P.
    Acta Oncol; 2011 Jan 01; 50(1):151-2. PubMed ID: 20843172
    [No Abstract] [Full Text] [Related]

  • 14. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC.
    Ann Oncol; 2002 Sep 01; 13(9):1469-78. PubMed ID: 12196374
    [Abstract] [Full Text] [Related]

  • 15. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E, Arbeitsgemeinschaft Internistische Onkologie.
    J Clin Oncol; 2008 Mar 20; 26(9):1435-42. PubMed ID: 18349393
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
    Eatock MM, Anthony DA, El-Abassi M, Wilson P, Paul J, Smith M, Soukop M, Evans TR.
    Br J Cancer; 2000 Jun 20; 82(12):1925-31. PubMed ID: 10864199
    [Abstract] [Full Text] [Related]

  • 19. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
    Thuss-Patience PC, Hofheinz RD, Arnold D, Florschütz A, Daum S, Kretzschmar A, Mantovani-Löffler L, Bichev D, Breithaupt K, Kneba M, Schumacher G, Glanemann M, Schlattmann P, Reichardt P, Gahn B.
    Ann Oncol; 2012 Nov 20; 23(11):2827-2834. PubMed ID: 22734012
    [Abstract] [Full Text] [Related]

  • 20. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G, Jauhri M, Negi A, Aggarwal S.
    Hematol Oncol Stem Cell Ther; 2010 Nov 20; 3(2):55-9. PubMed ID: 20543537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.